

Finn Gustafsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8207492/publications.pdf>

Version: 2024-02-01

241
papers

14,169
citations

71061

41
h-index

25770

108
g-index

246
all docs

246
docs citations

246
times ranked

10482
citing authors

#	ARTICLE	IF	CITATIONS
1	Association between routine measures of graft function and mortality in heart transplant recipients. <i>Heart</i> , 2022, 108, 307-311.	1.2	3
2	Bacterial and fungal bloodstream infections in solid organ transplant recipients: results from a Danish cohort with nationwide follow-up. <i>Clinical Microbiology and Infection</i> , 2022, 28, 391-397.	2.8	9
3	Prognostic value of myocardial flow reserve obtained by 82-rubidium positron emission tomography in long-term follow-up after heart transplantation. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 2555-2567.	1.4	4
4	Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical Trial. <i>Circulation: Heart Failure</i> , 2022, 15, .	1.6	17
5	Circulating Concentrations of C-Type Natriuretic Peptides Increase with Sacubitril/Valsartan Treatment in Healthy Young Men. <i>Clinical Chemistry</i> , 2022, 68, 713-720.	1.5	5
6	Survival and adverse events in patients with atrial fibrillation at left ventricular assist device implantation: an analysis of the European Registry for Patients with Mechanical Circulatory Support. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 61, 1164-1175.	0.6	6
7	Education and certification on heart failure of the <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation of the <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 249-253.	2.9	6
8	Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE Trial. <i>Diabetes</i> , 2022, 71, 812-820.	0.3	5
9	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 4-131.	2.9	820
10	Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction. <i>Drugs</i> , 2022, 82, 375-405.	4.9	7
11	Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE) Tj ETQq1 1 0.784314 rgBT /Overlock 112	0.3	112
12	Long-Term Follow-Up of DANISH (The Danish Study to Assess the Efficacy of ICDs in Patients With) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.6	28
13	The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker). <i>Cardiovascular Diabetology</i> , 2022, 21, 34.	2.7	10
14	Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure. <i>Circulation</i> , 2022, 145, 1592-1604.	1.6	54
15	Cardiac remodelling Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 927-943.	2.9	29
16	Suspicion, screening, and diagnosis of wild-type transthyretin amyloid cardiomyopathy: a systematic literature review. <i>ESC Heart Failure</i> , 2022, 9, 1524-1541.	1.4	8
17	Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care. <i>ESC Heart Failure</i> , 2022, 9, 1507-1523.	1.4	26
18	NT-proBNP and ICD in Nonischemic Systolic Heart Failure. <i>JACC: Heart Failure</i> , 2022, 10, 161-171.	1.9	4

#	ARTICLE	IF	CITATIONS
19	Oxygen Uptake During Activities of Daily Life in Patients Treated With a Left Ventricular Assist Device. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 982-990.	0.3	4
20	Healthcare resource use of patients with transthyretin amyloid cardiomyopathy. <i>ESC Heart Failure</i> , 2022, 9, 1636-1642.	1.4	4
21	Impact of serial measurements of tricuspid annular plane systolic excursion on mortality and morbidity after heart transplantation. <i>Clinical Transplantation</i> , 2022, , e14662.	0.8	0
22	Effect of influenza vaccination in solid organ transplant recipients: A nationwide population-based cohort study. <i>American Journal of Transplantation</i> , 2022, 22, 2409-2417.	2.6	6
23	Heart transplantation: focus on donor recovery strategies, left ventricular assist devices, and novel therapies. <i>European Heart Journal</i> , 2022, 43, 2237-2246.	1.0	23
24	Rate of thromboembolic and bleeding events in patients undergoing concomitant aortic valve surgery with left ventricular assist device implantation. <i>International Journal of Cardiology</i> , 2022, 359, 39-45.	0.8	3
25	Posttransplantation Diabetes Mellitus Among Solid Organ Recipients in a Danish Cohort. <i>Transplant International</i> , 2022, 35, 10352.	0.8	11
26	Cardiac remodelling – Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 944-958.	2.9	22
27	Three decades of heart transplantation: experience and long-term outcome. <i>Scandinavian Cardiovascular Journal</i> , 2022, 56, 65-72.	0.4	1
28	Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Reduced Ejection Fraction: Current Evidence and Future Perspectives. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2022, , .	1.2	1
29	The Effect of Empagliflozin on Contractile Reserve in Heart Failure: Prespecified Sub-Study of a Randomized, Double-Blind, and Placebo-Controlled Trial. <i>American Heart Journal</i> , 2022, 250, 57-57.	1.2	1
30	Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries. <i>ESC Heart Failure</i> , 2022, 9, 2528-2537.	1.4	12
31	Alcohol Intake in Patients With Cardiomyopathy and Heart Failure: Consensus and Controversy. <i>Circulation: Heart Failure</i> , 2022, 15, 101161CIRCHEARTFAILURE121009459.	1.6	18
32	Intermediate-dose prophylactic anticoagulation with low molecular weight heparin is safe after bioprosthetic artificial heart implantation. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 1214-1217.	0.3	8
33	Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2017-2026.	2.2	9
34	Outcomes following SARS-CoV-2 infection in individuals with and without solid organ transplantation – A Danish nationwide cohort study. <i>American Journal of Transplantation</i> , 2022, 22, 2627-2636.	2.6	21
35	Development and Validation of a Risk Score for Post-Transplant Lymphoproliferative Disorders among Solid Organ Transplant Recipients. <i>Cancers</i> , 2022, 14, 3279.	1.7	0
36	Impact of Hypothermia on Oxygenation Variables and Metabolism in Survivors of Out-of-Hospital Cardiac Arrest Undergoing Targeted Temperature Management at 33°C Versus 36°C. <i>Therapeutic Hypothermia and Temperature Management</i> , 2021, 11, 170-178.	0.3	6

#	ARTICLE	IF	CITATIONS
37	Predicting 10-year mortality in older adults using VO ₂ max, oxygen uptake efficiency slope and frailty class. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1148-1151.	0.8	6
38	Bioactive adrenomedullin in plasma is associated with biventricular filling pressures in patients with advanced heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 489-491.	2.9	10
39	The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT). <i>American Heart Journal</i> , 2021, 231, 137-146.	1.2	21
40	Dual Vasopressin Receptor Antagonism to Improve Congestion in Patients With Acute Heart Failure: Design of the AVANTI Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 233-241.	0.7	17
41	The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. <i>European Heart Journal</i> , 2021, 42, 1621-1631.	1.0	102
42	The contribution of cardiac and extracardiac factors to NT-proBNP concentrations in patients with advanced heart failure before and after left ventricular assist device implantation. <i>Peptides</i> , 2021, 135, 170420.	1.2	3
43	Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 106-116.	5.5	80
44	Biomarkers and Their Relation to Cardiac Function Late After Peripartum Cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2021, 27, 168-175.	0.7	13
45	Long-term prognosis following hospitalization for acute myocarditis – a matched nationwide cohort study. <i>Scandinavian Cardiovascular Journal</i> , 2021, 55, 264-269.	0.4	6
46	Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 754-764.	2.9	19
47	Exercise Tolerance in Patients Treated With a Durable Left Ventricular Assist Device: Importance of Myocardial Recovery. <i>Journal of Cardiac Failure</i> , 2021, 27, 486-493.	0.7	5
48	The association of prior carpal tunnel syndrome surgery with adverse cardiovascular outcomes and long-term mortality after aortic valve replacement. <i>IJC Heart and Vasculature</i> , 2021, 33, 100741.	0.6	0
49	Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy. <i>Circulation</i> , 2021, 143, 1852-1862.	1.6	65
50	An Observational Prospective Cohort Study of Incidence and Outcome of Streptococcus pneumoniae and Hemophilus influenzae Infections in Adult Solid Organ Transplant Recipients. <i>Microorganisms</i> , 2021, 9, 1371.	1.6	5
51	Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic). <i>Circulation</i> , 2021, 143, 2208-2210.	1.6	8
52	Left Ventricular Assist Devices at the Crossroad of Innovation in Advanced Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 1291-1294.	0.7	16
53	Progressive elimination of adverse events: the key to success for left ventricular assist devices. <i>European Journal of Heart Failure</i> , 2021, 23, 1401-1403.	2.9	0
54	Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1226-1237.	2.9	47

#	ARTICLE	IF	CITATIONS
55	Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 836.	3.0	95
56	Efficacy of the COVID-19 vaccine in heart transplant recipients: what we know and what we ignore. <i>European Journal of Heart Failure</i> , 2021, 23, 1560-1562.	2.9	3
57	Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-LVAD specialist healthcare provider: executive summary. <i>European Journal of Heart Failure</i> , 2021, 23, 1597-1609.	2.9	20
58	Host Genetics and Antiviral Immune Responses in Adult Patients With Multisystem Inflammatory Syndrome. <i>Frontiers in Immunology</i> , 2021, 12, 718744.	2.2	14
59	Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e020418.	1.6	12
60	Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry. <i>European Journal of Heart Failure</i> , 2021, 23, 2058-2069.	2.9	20
61	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021, 42, 3599-3726.	1.0	5,558
62	Two Decades of Cardiac Amyloidosis. <i>JACC: CardioOncology</i> , 2021, 3, 522-533.	1.7	20
63	Socioeconomic Disparities in Referral for Invasive Hemodynamic Evaluation for Advanced Heart Failure: A Nationwide Cohort Study. <i>Circulation: Heart Failure</i> , 2021, 14, e008662.	1.6	10
64	Hemodynamic Determinants of Activity Measured by Accelerometer in Patients With Stable Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 824-835.	1.9	4
65	Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist device-supported patients for the non-left ventricular assist device specialist healthcare provider: Part 2: at the emergency department. <i>ESC Heart Failure</i> , 2021, 8, 4409-4424.	1.4	7
66	Development and Dynamics of Cytomegalovirus UL97 Ganciclovir Resistance Mutations in Transplant Recipients Detected by Next Generation Sequencing. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab462.	0.4	4
67	HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community. <i>ESC Heart Failure</i> , 2021, 8, 4394-4408.	1.4	5
68	Comprehensive Physiological Modeling Provides Novel Insights Into Heart Failure With Preserved Ejection Fraction Physiology. <i>Journal of the American Heart Association</i> , 2021, 10, e021584.	1.6	12
69	HFA of the ESC position paper on the management of LVAD-supported patients for the non-LVAD specialist healthcare provider Part 3: at the hospital and discharge. <i>ESC Heart Failure</i> , 2021, 8, 4425-4443.	1.4	10
70	Prognostic Value of Peak Oxygen Uptake in Patients Supported With Left Ventricular Assist Devices (PRO-VAD). <i>JACC: Heart Failure</i> , 2021, 9, 758-767.	1.9	20
71	Incidence and Impact of Parvovirus B19 Infection in Seronegative Solid Organ Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2021, 224, 865-869.	1.9	5
72	Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden. <i>Open Heart</i> , 2021, 8, e001755.	0.9	19

#	ARTICLE	IF	CITATIONS
73	<scp>COVID</scp>â€”19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1806-1818.	2.9	32
74	Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial. <i>International Journal of Cardiovascular Imaging</i> , 2021, , 1.	0.7	6
75	Steroid withdrawal after heart transplantation in adults. <i>Transplant International</i> , 2021, 34, 2469.	0.8	0
76	PRospective Evaluation of natriuretic peptide-based reFERral of patients with chronic heart failure in primary care (PREFER): a real-world study. <i>Open Heart</i> , 2021, 8, e001630.	0.9	0
77	23. Development and Validation of a Risk Score for Post-transplant Lymphoproliferative Disorders among Solid Organ Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2021, 8, S15-S16.	0.4	0
78	Computed Tomographyâ€”Estimated Right Ventricular Function and Exercise Capacity in Patients with Continuous-Flow Left Ventricular Assist Devices. <i>ASAIO Journal</i> , 2020, 66, 8-16.	0.9	12
79	Performance of Prognostic Risk Scores in Heart Failure Patients: Do Sex Differences Exist?. <i>Canadian Journal of Cardiology</i> , 2020, 36, 45-53.	0.8	9
80	Effect of Heart Rate Reserve on Exercise Capacity in Patients Treated with a Continuous Left Ventricular Assist Device. <i>ASAIO Journal</i> , 2020, 66, 160-165.	0.9	11
81	Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study. <i>Transplantation</i> , 2020, 104, 154-164.	0.5	25
82	Pulmonary artery pulsatility index: physiological basis and clinical application. <i>European Journal of Heart Failure</i> , 2020, 22, 32-38.	2.9	72
83	First Letâ€™s Try â€” Will the Success of New Therapies Paradoxically Challenge Outcomes in Advanced Heart Failure?. <i>Circulation: Heart Failure</i> , 2020, 13, e006610.	1.6	1
84	If it ain't broken, don't fix it (but if it is, make sure you know): aortic valve interventions during left ventricular assist device implantation. <i>European Journal of Heart Failure</i> , 2020, 22, 1888-1890.	2.9	1
85	Intravascular ultrasoundâ€”guided selection for early noninvasive cardiac allograft vasculopathy screening in heart transplant recipients. <i>Clinical Transplantation</i> , 2020, 34, e14124.	0.8	7
86	Evaluation of an electronic, patientâ€”focused management system aimed at preventing cytomegalovirus disease following solid organ transplantation. <i>Transplant Infectious Disease</i> , 2020, 22, e13252.	0.7	23
87	Clinical presentation and outcomes in women and men with advanced heart failure. <i>Scandinavian Cardiovascular Journal</i> , 2020, 54, 361-368.	0.4	4
88	Is aspirin needed to prevent thrombotic events in patients treated with a HeartMate 3 left ventricular assist device?. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 526-528.	0.3	4
89	Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial. <i>American Heart Journal</i> , 2020, 228, 47-56.	1.2	61
90	Risk Factors for Morbidity and Mortality Following Hospitalization for Pericarditis. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2623-2631.	1.2	11

#	ARTICLE	IF	CITATIONS
91	Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2740-2751.	1.2	57
92	When Making Your Bed Feels Like Running a Marathon. <i>Circulation: Heart Failure</i> , 2020, 13, e007993.	1.6	1
93	Catheter ablation and mortality, stroke and heart failure readmission with atrial fibrillation. <i>Open Heart</i> , 2020, 7, e001369.	0.9	3
94	Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis. <i>Journal of the American College of Cardiology</i> , 2020, 76, 767-777.	1.2	61
95	Identification of Patients with New-Onset Heart Failure and Reduced Ejection Fraction in Danish Administrative Registers. <i>Clinical Epidemiology</i> , 2020, Volume 12, 589-594.	1.5	17
96	Plasma Somatostatin in Advanced Heart Failure: Association with Cardiac Filling Pressures and Outcome. <i>Cardiology</i> , 2020, 145, 769-778.	0.6	3
97	Recessive Inheritance of a Rare Variant in the Nuclear Mitochondrial Gene for <i>AARS2</i> in Late-Onset Dilated Cardiomyopathy. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, 560-562.	1.6	6
98	Two-year outcome after implantation of a full magnetically levitated left ventricular assist device: results from the ELEVATE Registry. <i>European Heart Journal</i> , 2020, 41, 3801-3809.	1.0	49
99	Use of T Cell Mediated Immune Functional Assays for Adjustment of Immunosuppressive or Anti-infective Agents in Solid Organ Transplant Recipients: A Systematic Review. <i>Frontiers in Immunology</i> , 2020, 11, 567715.	2.2	10
100	Impact of Interatrial Shunts on Invasive Hemodynamics and Exercise Tolerance in Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2020, 9, e016760.	1.6	19
101	Reduced Diuretic Dose in Patients Treated With Eplerenone. <i>Circulation: Heart Failure</i> , 2020, 13, e006597.	1.6	11
102	Tuberculosis among Patients Undergoing Solid Organ Transplantation or Dialysis in a Low-Endemic Country, 2004-2017. <i>Tuberculosis Research and Treatment</i> , 2020, 2020, 1-7.	0.2	4
103	Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De novo heart transplant recipients: Design of the randomized controlled EVOLVD trial. <i>Clinical Transplantation</i> , 2020, 34, e13984.	0.8	15
104	Predictors of Physical Capacity 6 Months After Implantation of a Full Magnetically Levitated Left Ventricular Assist Device: An Analysis From the ELEVATE Registry. <i>Journal of Cardiac Failure</i> , 2020, 26, 580-587.	0.7	8
105	Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. <i>Nature Reviews Cardiology</i> , 2020, 17, 641-655.	6.1	143
106	Comparative analysis of regional outcomes and adverse events after continuous-flow left ventricular assist device implantation: An IMACS analysis. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 904-914.	0.3	4
107	Measles, Mumps, Rubella, and Varicella Zoster Virus Serology and Infections in Solid Organ Transplant Recipients During the First Year Posttransplantation. <i>Clinical Infectious Diseases</i> , 2020, 73, e3733-e3739.	2.9	7
108	Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients. <i>ESC Heart Failure</i> , 2020, 7, 567-576.	1.4	2

#	ARTICLE	IF	CITATIONS
109	Refining the role of carpal tunnel syndrome in cardiac amyloidosis. <i>European Journal of Heart Failure</i> , 2020, 22, 516-518.	2.9	2
110	Right ventricular transverse displacement increases following cardiac surgery: possibly compensating loss in tricuspid annular plane systolic excursion (TAPSE). <i>Journal of Clinical Monitoring and Computing</i> , 2020, 34, 1139-1148.	0.7	10
111	The Effect of Common Interventions in the Intensive Care Unit on Right Ventricular Function After Cardiac Surgery—An Intervention Study. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2020, 34, 1211-1219.	0.6	4
112	Outcome after heart–lung or lung transplantation in patients with Eisenmenger syndrome. <i>Heart</i> , 2020, 106, 127-132.	1.2	22
113	Mild acute cellular rejection and development of cardiac allograft vasculopathy assessed by intravascular ultrasound and coronary angiography in heart transplant recipients—a SCHEDULE trial substudy. <i>Transplant International</i> , 2020, 33, 517-528.	0.8	4
114	Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort. <i>European Journal of Heart Failure</i> , 2020, 22, 1777-1785.	2.9	53
115	Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma. <i>Endocrine Connections</i> , 2020, 9, 438-444.	0.8	6
116	Determinants of Functional Capacity and Quality of Life After Implantation of a Durable Left Ventricular Assist Device. <i>Cardiac Failure Review</i> , 2020, 6, e29.	1.2	6
117	1079. The Risk of Cytomegalovirus (CMV) Infection and Recurrence Among Solid Organ Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2020, 7, S567-S568.	0.4	1
118	Sacubitril/Valsartan Augments Postprandial Plasma Concentrations of Active GLP-1 When Combined With Sitagliptin in Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3868-3876.	1.8	18
119	Relationship between invasive hemodynamics and liver function in advanced heart failure. <i>Scandinavian Cardiovascular Journal</i> , 2019, 53, 235-246.	0.4	4
120	Immune function as predictor of infectious complications and clinical outcome in patients undergoing solid organ transplantation (the ImmuneMo:SOT study): a prospective non-interventional observational trial. <i>BMC Infectious Diseases</i> , 2019, 19, 573.	1.3	10
121	Interplay of pump design elements and bleeding predilection—Mechanisms for a forward momentum. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 817-819.	0.3	2
122	Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz215.	0.4	21
123	Association of Carpal Tunnel Syndrome With Amyloidosis, Heart Failure, and Adverse Cardiovascular Outcomes. <i>Journal of the American College of Cardiology</i> , 2019, 74, 15-23.	1.2	77
124	“Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation”. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 3125-3135.	1.2	10
125	Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial). <i>American Journal of Cardiology</i> , 2019, 124, 1912-1917.	0.7	13
126	Duration of Heart Failure and Effect of Defibrillator Implantation in Patients With Nonischemic Systolic Heart Failure. <i>Circulation: Heart Failure</i> , 2019, 12, e006022.	1.6	2

#	ARTICLE	IF	CITATIONS
127	A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus. <i>International Journal of Cardiology</i> , 2019, 297, 83-90.	0.8	42
128	Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF). <i>Trials</i> , 2019, 20, 374.	0.7	35
129	2019 EACTS Expert Consensus on long-term mechanical circulatory support. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 56, 230-270.	0.6	255
130	Severe loss of right ventricular longitudinal contraction occurs after cardiopulmonary bypass in patients with preserved right ventricular output. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 1661-1670.	0.7	23
131	Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 321-332.	1.9	33
132	Prevalence of heart failure and other risk factors among first-degree relatives of women with peripartum cardiomyopathy. <i>Heart</i> , 2019, 105, 1057-1062.	1.2	10
133	Incidence Rates and Risk Factors of <i>Clostridioides difficile</i> Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz086.	0.4	17
134	The impact of implantable cardioverter-defibrillator implantation on health-related quality of life in the DANISH trial. <i>Europace</i> , 2019, 21, 900-908.	0.7	10
135	Continuous-flow LVADs in the Nordic countries: complications and mortality and its predictors. <i>Scandinavian Cardiovascular Journal</i> , 2019, 53, 14-20.	0.4	5
136	Lung diffusion capacity in advanced heart failure: relation to central haemodynamics and outcome. <i>ESC Heart Failure</i> , 2019, 6, 379-387.	1.4	15
137	Effects of Interatrial Shunt on Pulmonary Vascular Function in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2539-2550.	1.2	69
138	The Potential Role of Transcatheter Heart Valve Interventions in Heart Failure Treatment. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 166-168.	1.1	1
139	Postmarket Experience With HeartMate 3 Left Ventricular Assist Device: 30-Day Outcomes From the ELEVATE Registry. <i>Annals of Thoracic Surgery</i> , 2019, 107, 33-39.	0.7	19
140	Right Ventricular and Pulmonary Vascular Function are Influenced by Age and Volume Expansion in Healthy Humans. <i>Journal of Cardiac Failure</i> , 2019, 25, 51-59.	0.7	13
141	Pulmonary Arterial Wedge Pressure at Rest and During Exercise in Healthy Adults: A Systematic Review and Meta-analysis. <i>Journal of Cardiac Failure</i> , 2019, 25, 114-122.	0.7	25
142	Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period. <i>ESC Heart Failure</i> , 2019, 6, 174-181.	1.4	43
143	Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction. <i>ESC Heart Failure</i> , 2019, 6, 62-69.	1.4	45
144	Occult cardiac amyloidosis?. <i>Aging</i> , 2019, 11, 8739-8740.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial). <i>BMJ Open</i> , 2019, 9, e029098.	0.8	3
146	Authors' reply re: Subsequent reproductive outcome among women with peripartum cardiomyopathy: a nationwide study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018, 125, 1040-1041.	1.1	0
147	Characteristics and long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta-analysis. <i>ESC Heart Failure</i> , 2018, 5, 685-694.	1.4	53
148	When the VEST Does Not Fit. <i>Circulation: Heart Failure</i> , 2018, 11, e005116.	1.6	2
149	Low-Dose Aspirin in Heart Failure Not Complicated by Atrial Fibrillation. <i>JACC: Heart Failure</i> , 2018, 6, 156-167.	1.9	11
150	Layer-specific deformation analysis in severe aortic valve stenosis, primary mitral valve regurgitation, and healthy individuals validated against invasive hemodynamic measurements of heart function. <i>Echocardiography</i> , 2018, 35, 170-178.	0.3	3
151	Psychological adaptation after peripartum cardiomyopathy: A qualitative study. <i>Midwifery</i> , 2018, 62, 52-60.	1.0	6
152	Heart transplantation in arrhythmogenic right ventricular cardiomyopathy – Experience from the Nordic ARVC Registry. <i>International Journal of Cardiology</i> , 2018, 250, 201-206.	0.8	25
153	The European Registry for Patients with Mechanical Circulatory Support (EUROMACS) of the European Association for Cardio-Thoracic Surgery (EACTS): second report. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 309-316.	0.6	121
154	Resting and exercise haemodynamics in relation to six-minute walk test in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 715-722.	2.9	41
155	Screening for heart transplantation and left ventricular assist system: results from the ScREening for advanced Heart Failure treatment (SEEHF) study. <i>European Journal of Heart Failure</i> , 2018, 20, 152-160.	2.9	29
156	Increased blood pressure and aortic stiffness among abusers of anabolic androgenic steroids. <i>Journal of Hypertension</i> , 2018, 36, 277-285.	0.3	49
157	Medical and mechanical unloading in advanced heart failure: hope for cardiac recovery?. <i>European Journal of Heart Failure</i> , 2018, 20, 175-177.	2.9	1
158	1597. Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus (CMV) Infection and Disease in Solid Organ Transplant (SOT) Recipients. <i>Open Forum Infectious Diseases</i> , 2018, 5, S500-S500.	0.4	0
159	Impact of CMV PCR Blips in Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation. <i>Transplantation Direct</i> , 2018, 4, e355.	0.8	12
160	Classification of death causes after transplantation (CLASS). <i>Medicine (United States)</i> , 2018, 97, e11564.	0.4	14
161	1579. Evaluation of MATCH: an Electronic Individual Patient-Focused Management System Aimed at Preventing Cytomegalovirus Disease Following Solid Organ Transplantation. <i>Open Forum Infectious Diseases</i> , 2018, 5, S493-S493.	0.4	0
162	1584. Development and Dynamics of Cytomegalovirus UL97 Ganciclovir Resistance Mutations in Transplant Recipients Detected by Next-generation Sequencing. <i>Open Forum Infectious Diseases</i> , 2018, 5, S495-S496.	0.4	0

#	ARTICLE	IF	CITATIONS
163	Repetitive levosimendan treatment in the management of advanced heart failure. <i>European Heart Journal Supplements</i> , 2018, 20, I11-I20.	0.0	23
164	Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients. <i>Circulation: Heart Failure</i> , 2018, 11, e004050.	1.6	39
165	Impact of Baseline Hemodynamics on the Effects of a Transcatheter Interatrial Shunt Device in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2018, 11, e004540.	1.6	23
166	Six-month outcomes after treatment of advanced heart failure with a full magnetically levitated continuous flow left ventricular assist device: report from the ELEVATE registry. <i>European Heart Journal</i> , 2018, 39, 3454-3460.	1.0	62
167	Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 1505-1535.	2.9	555
168	Cardiac systolic dysfunction in past illicit users of anabolic androgenic steroids. <i>American Heart Journal</i> , 2018, 203, 49-56.	1.2	40
169	Hemodynamic effects of short-term infusion of a vasopressin V1A/V2 receptor antagonist conivaptan in patients with chronic heart failure during submaximal exercise. <i>American Heart Journal</i> , 2018, 203, 101-104.	1.2	4
170	Copeptin levels and invasive hemodynamics in patients with advanced heart failure. <i>Biomarkers in Medicine</i> , 2018, 12, 861-870.	0.6	3
171	Bromocriptine for the treatment of peripartum cardiomyopathy: comparison of outcome with a Danish cohort. <i>European Heart Journal</i> , 2018, 39, 3476-3477.	1.0	9
172	Cardiac procholecystokinin expression during haemodynamic changes in the mammalian heart. <i>Peptides</i> , 2018, 108, 7-13.	1.2	7
173	The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1569-1580.	1.2	28
174	Management of patients with cardiogenic shock on temporary mechanical circulatory support: urgent transplantation or on to the next pump?. <i>European Journal of Heart Failure</i> , 2018, 20, 187-189.	2.9	10
175	Clinical features and determinants of VO ₂ peak in de novo heart transplant recipients. <i>World Journal of Transplantation</i> , 2018, 8, 188-197.	0.6	10
176	Measures of right ventricular function after transcatheter versus surgical aortic valve replacement. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2017, 24, iw350.	0.5	17
177	Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes. <i>European Journal of Heart Failure</i> , 2017, 19, 595-602.	2.9	228
178	Insulin sensitivity in relation to fat distribution and plasma adipocytokines among abusers of anabolic androgenic steroids. <i>Clinical Endocrinology</i> , 2017, 87, 249-256.	1.2	33
179	Vasopressin and Vasopressin Antagonists in Heart Failure. <i>Handbook of Experimental Pharmacology</i> , 2017, 243, 307-328.	0.9	9
180	Pulmonary venous remodeling in COPD, pulmonary hypertension and idiopathic pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2017, 7, 514-521.	0.8	8

#	ARTICLE	IF	CITATIONS
181	Peripartum cardiomyopathy in Denmark: a retrospective, population-based study of incidence, management and outcome. <i>European Journal of Heart Failure</i> , 2017, 19, 1712-1720.	2.9	64
182	The Influence of Age on Hemodynamic Parameters During Rest and Exercise in Healthy Individuals. <i>JACC: Heart Failure</i> , 2017, 5, 337-346.	1.9	108
183	The first-in-man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure: the <sc>BEAT-HF</sc> trial. <i>European Journal of Heart Failure</i> , 2017, 19, 566-575.	2.9	53
184	Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with mid-range and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 1690-1697.	2.9	34
185	Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure. <i>Circulation</i> , 2017, 136, 1772-1780.	1.6	134
186	Influence of renal impairment on aldosterone status, calcium metabolism, and vasopressin activity in outpatients with systolic heart failure. <i>ESC Heart Failure</i> , 2017, 4, 554-562.	1.4	4
187	Effect of everolimus vs calcineurin inhibitors on quality of life in heart transplant recipients during a 3-year follow-up: Results of a randomized controlled trial (<sc>SCHEDULE</sc>). <i>Clinical Transplantation</i> , 2017, 31, e13038.	0.8	2
188	Heart transplantation turns 50 and is going strong. <i>European Journal of Heart Failure</i> , 2017, 19, 1564-1565.	2.9	2
189	Longitudinal shortening of sub-epicardial myocytes in severe ischaemic cardiomyopathy: insights from gadolinium contrast cardiac magnetic resonance imaging. <i>ESC Heart Failure</i> , 2017, 4, 670-674.	1.4	1
190	An ISHLT consensus document for prevention and management strategies for mechanical circulatory support infection. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 1137-1153.	0.3	142
191	Pump speed modulations and sub-maximal exercise tolerance in left ventricular assist device recipients: A double-blind, randomized trial. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 36-41.	0.3	38
192	Right ventricular dysfunction after cardiac surgery – diagnostic options. <i>Scandinavian Cardiovascular Journal</i> , 2017, 51, 114-121.	0.4	18
193	The inodilator levosimendan as a treatment for acute heart failure in various settings. <i>European Heart Journal Supplements</i> , 2017, 19, C2-C7.	0.0	19
194	Classification of Death Causes after Transplantation (CLASS): Evaluation of Methodology and Initial Results. <i>Open Forum Infectious Diseases</i> , 2017, 4, S703-S703.	0.4	0
195	Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study. <i>PLoS ONE</i> , 2016, 11, e0161208.	1.1	108
196	Copeptin in Heart Failure. <i>Advances in Clinical Chemistry</i> , 2016, 73, 29-64.	1.8	20
197	Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial. <i>Transplant International</i> , 2016, 29, 819-829.	0.8	39
198	Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 117.	0.7	21

#	ARTICLE	IF	CITATIONS
199	Wound complications and surgical events in de novo heart transplant patients treated with everolimus: Post-hoc analysis of the SCHEDULE trial. <i>International Journal of Cardiology</i> , 2016, 210, 80-84.	0.8	10
200	Early changes in left atrial volume after acute myocardial infarction. Relation to invasive hemodynamics at rest and during exercise. <i>International Journal of Cardiology</i> , 2016, 223, 717-722.	0.8	10
201	Incidence of cancer in patients with chronic heart failure: a long-term follow-up study. <i>European Journal of Heart Failure</i> , 2016, 18, 260-266.	2.9	158
202	Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2016, 375, 1221-1230.	13.9	1,350
203	Peripartum cardiomyopathy: a systematic literature review. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2016, 95, 1205-1219.	1.3	23
204	Effect of everolimus initiation and early calcineurin inhibitor withdrawal on myocardial FOXP3 + regulatory T cells in heart transplantation. <i>Transplant Immunology</i> , 2016, 38, 75-77.	0.6	13
205	Neurohormonal activation and exercise tolerance in patients supported with a continuous-flow left ventricular assist device. <i>International Journal of Cardiology</i> , 2016, 220, 196-200.	0.8	3
206	Use of digoxin and risk of death or readmission for heart failure and sinus rhythm: A nationwide propensity score matched study. <i>International Journal of Cardiology</i> , 2016, 221, 944-950.	0.8	12
207	Ramp Study Hemodynamics, Functional Capacity, and Outcome in Heart Failure Patients with Continuous-Flow Left Ventricular Assist Devices. <i>ASAIO Journal</i> , 2016, 62, 442-446.	0.9	23
208	Pulmonary hypertension as a risk factor of mortality after lung transplantation. <i>Clinical Transplantation</i> , 2016, 30, 357-364.	0.8	24
209	A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE) Tj ETQq1 1 0.784314 rgBT / Over	0.3	238
210	Exercise Intolerance in Heart Failure: Did We Forget the Brain?. <i>Canadian Journal of Cardiology</i> , 2016, 32, 475-484.	0.8	26
211	Design and rationale of the HITTS randomized controlled trial: Effect of High-intensity Interval Training in de novo Heart Transplant Recipients in Scandinavia. <i>American Heart Journal</i> , 2016, 172, 96-105.	1.2	13
212	Urinary Proteomics Pilot Study for Biomarker Discovery and Diagnosis in Heart Failure with Reduced Ejection Fraction. <i>PLoS ONE</i> , 2016, 11, e0157167.	1.1	42
213	Optimal Cardiac Resynchronization Therapy Pacing Rate in Non-Ischemic Heart Failure Patients: A Randomized Crossover Pilot Trial. <i>PLoS ONE</i> , 2015, 10, e0138124.	1.1	2
214	Cardiomyocyte Expression and Cell-specific Processing of Procholecystokinin. <i>Journal of Biological Chemistry</i> , 2015, 290, 6837-6843.	1.6	24
215	Iron deficiency: Prevalence and relation to cardiovascular biomarkers in heart failure outpatients. <i>International Journal of Cardiology</i> , 2015, 195, 143-148.	0.8	20
216	Effect of moderate- versus high-intensity exercise on vascular function, biomarkers and quality of life in heart transplant recipients: A randomized, crossover trial. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1033-1041.	0.3	52

#	ARTICLE	IF	CITATIONS
217	The Influence of Diabetes Mellitus on Midregional Proadrenomedullin Concentrations and Prognostic Value in Heart Failure Outpatients. <i>Journal of Cardiac Failure</i> , 2015, 21, 250-257.	0.7	5
218	Clinical outcome of transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel implant. <i>International Journal of Cardiology</i> , 2015, 187, 227-228.	0.8	30
219	Exercise in heart failure patients supported with a left ventricular assist device. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 489-496.	0.3	101
220	Outcomes and hospital admissions during long-term support with a HeartMate II. <i>Scandinavian Cardiovascular Journal</i> , 2015, 49, 367-75.	0.4	6
221	602Elevation in Liver Transaminase (ALT-flares) in Transplant (TX) Recipients: Risk factors and Consequences. <i>Open Forum Infectious Diseases</i> , 2014, 1, S26-S26.	0.4	0
222	605Clinically Applied Variation in Replication Kinetics During Episodes of Post-Transplant Cytomegalovirus (CMV) Infections. <i>Open Forum Infectious Diseases</i> , 2014, 1, S27-S27.	0.4	0
223	1168Use of First Positive Cytomegalovirus (CMV) PCR Determination to Differentiate a Viral Blip From Established CMV Infection in Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2014, 1, S347-S347.	0.4	0
224	Plasma NGAL and glomerular filtration rate in cardiac transplant recipients treated with standard or reduced calcineurin inhibitor levels. <i>Biomarkers in Medicine</i> , 2014, 8, 239-245.	0.6	4
225	Mitral regurgitation " Unmet need for improved management strategies. <i>IJC Heart and Vasculature</i> , 2014, 5, 26-41.	0.6	6
226	Nationwide trends in development of heart failure and mortality after first-time myocardial infarction 1997-2010: A Danish cohort study. <i>European Journal of Internal Medicine</i> , 2014, 25, 731-738.	1.0	33
227	Influence of renal impairment on myocardial function in outpatients with systolic heart failure: An echocardiographic and cardiac biomarker study. <i>International Journal of Cardiology</i> , 2014, 177, 942-948.	0.8	6
228	Relationships Between Biomarkers and Left Ventricular Filling Pressures at Rest and During Exercise in Patients After Myocardial Infarction. <i>Journal of Cardiac Failure</i> , 2014, 20, 959-967.	0.7	12
229	Effect of increasing pump speed during exercise on peak oxygen uptake in heart failure patients supported with a continuous-flow left ventricular assist device. A double-blind randomized study. <i>European Journal of Heart Failure</i> , 2014, 16, 403-408.	2.9	74
230	Effects of an Interatrial Shunt on Rest and Exercise Hemodynamics: Results of a Computer Simulation in Heart Failure. <i>Journal of Cardiac Failure</i> , 2014, 20, 212-221.	0.7	111
231	Targeting the aldosterone pathway in cardiovascular disease. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 135-145.	1.0	6
232	How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?. <i>Journal of Hypertension</i> , 2010, 28, 1595-1598.	0.3	12
233	Maximizing scientific knowledge from randomized clinical trials. <i>American Heart Journal</i> , 2010, 159, 937-943.	1.2	12
234	Incidence and predictors of hospitalization or death in patients managed in multidisciplinary heart failure clinics. <i>European Journal of Heart Failure</i> , 2009, 11, 413-419.	2.9	18

#	ARTICLE	IF	CITATIONS
235	Renal-sparing strategies in cardiac transplantation. <i>Current Opinion in Organ Transplantation</i> , 2009, 14, 566-570.	0.8	11
236	Treatment with beta-blockers in nurse-led heart failure clinics: Titration efficacy and predictors of failure. <i>European Journal of Heart Failure</i> , 2007, 9, 910-916.	2.9	34
237	Commentary 2. Evidence-based Cardiovascular Medicine, 2005, 9, 219-220.	0.0	0
238	Heart failure clinics and outpatient management: review of the evidence and call for quality assurance. <i>European Heart Journal</i> , 2004, 25, 1596-1604.	1.0	86
239	Effect of age on short and long-term mortality in patients admitted to hospital with congestive heart failure. <i>European Heart Journal</i> , 2004, 25, 1711-1717.	1.0	62
240	False-positive defects in technetium-99m sestamibi myocardial single-photon emission tomography in healthy athletes with left ventricular hypertrophy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998, 25, 1308-1312.	3.3	21
241	Aortic Pulsatility Index: A New Haemodynamic Measure with Prognostic Value in Advanced Heart Failure. <i>Cardiac Failure Review</i> , 0, 8, .	1.2	3